Results 21 to 30 of about 1,572 (142)

First-line tagraxofusp induces durable responses with prolonged survival in adults younger than 50 years with blastic plasmacytoid dendritic cell neoplasm: Post hoc analysis of a phase 2 trial. [PDF]

Br J Haematol
British Journal of Haematology, Volume 207, Issue 6, Page 2592-2596, December 2025.
Stein AS, Lane AA, Sweet KL, Vasu S, Tosolini A, Katsetos J, Konopleva M, Pemmaraju N.   +7 more
europepmc   +2 more sources

Blastic Plasmacytoid Dendritic Cell Neoplasm

Current Treatment Options in Oncology, 2019
While there is a high initial response rate with standard chemotherapeutic regimens for blastic plasmacytoid dendritic cell neoplasm (BPDCN), the responses are typically not durable and this remains a very aggressive disease with generally poor outcomes.
Daniel, Kerr, Ling, Zhang, Lubomir, Sokol   +2 more
  +7 more sources

MRD IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM

Hematology, Transfusion and Cell Therapy, 2022
Objective: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare disease with an aggressive course. Plasmacytoid dendritic cells (PDCs) are a component of the innate immune response: they secrete large amounts of type I interferons ...
Aleksandra Palladina, Alexander Popa, Timur Valiev, Nikolay Tupitsyn   +3 more
doaj   +1 more source

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

Haematologica, 2015
Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never been prospectively ...
Fanny Angelot-Delettre, Anne Roggy, Arthur E. Frankel, Baptiste Lamarthee, Estelle Seilles, Sabeha Biichle, Bernard Royer, Eric Deconinck, Eric K. Rowinsky, Christopher Brooks, Valerie Bardet, Blandine Benet, Hind Bennani, Zehaira Benseddik, Agathe Debliquis, Daniel Lusina, Mikael Roussel, Françoise Solly, Michel Ticchioni, Philippe Saas, Francine Garnache-Ottou   +20 more
doaj   +1 more source

Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm

Haematologica, 2017
Blastic plasmacytoid dendritic cell neoplasm is an aggressive hematologic malignancy with a poor prognosis. No consensus regarding optimal treatment modalities is currently available. Targeting the nuclear factor-kappa B pathway is considered a promising
Laure Philippe, Adam Ceroi, Elodie Bôle-Richard, Alizée Jenvrin, Sabeha Biichle, Sophie Perrin, Samuel Limat, Francis Bonnefoy, Eric Deconinck, Philippe Saas, Francine Garnache-Ottou, Fanny Angelot-Delettre   +11 more
doaj   +1 more source

Disseminated blastic plasmacytoid dendritic cell neoplasm [PDF]

Blood, 2015
![Figure][1] A 63-year-old man presented with cutaneous nodules. Workup revealed anemia, thrombocytopenia, monocytosis, and 5% circulating “blasts.” Bone marrow sampling showed 33% immature-appearing cells (panel A), with occasional “tadpole” appearance (panel A, lower inset) and ...
Sanam Loghavi, Joseph D. Khoury
openaire   +2 more sources

Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm

Haematologica, 2009
Acute myeloid leukemia carrying cytoplasmic mutated nucleophosmin (NPMc+ AML) and blastic plasmacytoid dendritic cell neoplasm have been included as new entities in the 4th edition (2008) WHO classification of myeloid neoplasms. These conditions may show
Fabio Facchetti, Stefano A. Pileri, Claudio Agostinelli, Maria Paola Martelli, Marco Paulli, Adriano Venditti, Massimo F Martelli, Brunangelo Falini   +7 more
doaj   +1 more source

Blastic plasmacytoid dendritic cell neoplasm of the uterus [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2020
Introduction. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and very aggressive hematological malignancy derived from precursor of the plasmacytoid dendritic cell.
Đurđević Predrag, Todorović Željko, Jovanović Danijela, Čekerevac Ivan, Novković Ljiljana, Mitrović Slobodanka, Čemerikić Vesna, Otašević Vladimir, Antić Darko   +8 more
doaj   +1 more source

Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature

Journal of Medical Case Reports, 2021
Background We describe a patient with blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement and the outcome of venetoclax use in this setting.
Nil Albiol, Silvana Novelli, Anna Mozos, Marta Pratcorona, Rodrigo Martino, Jorge Sierra   +5 more
doaj   +1 more source

Blastic plasmacytoid dendritic cell neoplasm with genetic mutations in multiple epigenetic modifiers: a case report

Journal of International Medical Research, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematodermic malignancy derived from plasmacytoid dendritic cell precursors. Despite advances in our understanding of tumor cell surface markers, the pathogenesis of BPDCN remains
Xinmei Dang, Di Zhou, Lingjun Meng, Lintao Bi   +3 more
doaj   +1 more source